CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driver
暂无分享,去创建一个
[1] M. Sugaya,et al. A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab , 2021, Dermatologic therapy.
[2] R. Hoppe,et al. Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome , 2020, Advances in radiation oncology.
[3] D. Pookot,et al. Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4 , 2020, Journal for ImmunoTherapy of Cancer.
[4] K. Abe,et al. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma , 2020, AntiCancer Research.
[5] M. Sznol,et al. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study , 2020, Clinical Cancer Research.
[6] M. Pulitzer,et al. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping , 2020, Cytometry. Part B, Clinical cytometry.
[7] S. Aiba,et al. Successful treatment of mogamulizumab‐resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment , 2020, Dermatologic therapy.
[8] A. Rook,et al. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy , 2020, Expert review of anticancer therapy.
[9] Craig B. Davis,et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors , 2019, Journal of Immunotherapy for Cancer.
[10] C. Elmets,et al. Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study , 2019, Blood.
[11] K. Muro,et al. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors , 2019, Clinical Cancer Research.
[12] M. Sugaya,et al. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome. , 2019, Acta dermato-venereologica.
[13] P. LoRusso,et al. Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer. , 2019 .
[14] I. Sahin,et al. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma , 2019, OncoTargets and therapy.
[15] L. Moscinski,et al. Naïve/memory T‐cell phenotypes in leukemic cutaneous T‐cell lymphoma: Putative cell of origin overlaps disease classification , 2018, Cytometry. Part B, Clinical cytometry.
[16] C. Elmets,et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.
[17] D. Mestel,et al. S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow‐up (ICD10 C82 ‐ C86) , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[18] Mark S. Sundrud,et al. Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. , 2017, The Journal of investigative dermatology.
[19] G. Deng. Tumor-infiltrating regulatory T cells: origins and features. , 2018, American journal of clinical and experimental immunology.
[20] H. Tagawa,et al. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas , 2017, Haematologica.
[21] J. Sampson,et al. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3 , 2017, Expert review of clinical immunology.
[22] R. Wilcox,et al. Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management , 2017, American journal of hematology.
[23] T. Waldmann,et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T‐cell malignancies , 2017, American journal of hematology.
[24] C. Klemke,et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. , 2017, European journal of cancer.
[25] D. Sasseville,et al. Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators , 2017, Oncoimmunology.
[26] C. Bocsan,et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies , 2017, OncoTargets and therapy.
[27] N. Mongan,et al. Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover , 2016, Seminars in Immunopathology.
[28] M. Donia,et al. CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment , 2016, Oncoimmunology.
[29] A. Barrett,et al. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia , 2016, Clinical Cancer Research.
[30] M. Felcht,et al. Sézary syndrome: old enigmas, new targets , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[31] C. Querfeld,et al. Tumor microenvironment in mycosis fungoides and Sézary syndrome , 2016, Current opinion in oncology.
[32] R. Cowan,et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Solari,et al. Targeting chemokine receptors in disease – a case study of CCR4 , 2015, European journal of pharmacology.
[34] Shinichi Sato,et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis , 2015, The Journal of dermatology.
[35] J. Jorgensen,et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. , 2015, Blood.
[36] Rei Watanabe,et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells , 2015, Science Translational Medicine.
[37] R. Ueda,et al. Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.
[38] L. Michel,et al. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. , 2015, The Journal of investigative dermatology.
[39] K. Matsushima,et al. CCR4 and its ligands: from bench to bedside. , 2015, International immunology.
[40] L. Staudt,et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma , 2014, The Journal of experimental medicine.
[41] M. Goswami,et al. Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome , 2014, Clinical Cancer Research.
[42] M. Taniwaki,et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Colombatti,et al. The Inflammatory Chemokine CCL5 and Cancer Progression , 2014, Mediators of inflammation.
[44] M.-H. Chen,et al. The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage. , 2014, European review for medical and pharmacological sciences.
[45] D. Sasseville,et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. , 2013, Blood.
[46] L. Cerroni,et al. FOXP3 in Sequential Biopsies of Progressive Mycosis Fungoides , 2012, The American Journal of dermatopathology.
[47] K. Sutherland,et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patients , 2012, American journal of hematology.
[48] X. Ke,et al. The Four types of Tregs in malignant lymphomas , 2011, Journal of hematology & oncology.
[49] C. Geisler,et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. , 2011, The Journal of investigative dermatology.
[50] R. Pomerantz,et al. Infectious agents in cutaneous T-cell lymphoma. , 2011, Journal of the American Academy of Dermatology.
[51] D. Minor,et al. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. , 2010, Cancer biotherapy & radiopharmaceuticals.
[52] James J. Campbell,et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. , 2010, Blood.
[53] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[54] C. Klemke,et al. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. , 2009, The Journal of investigative dermatology.
[55] Chieh-Shan Wu,et al. Differential CCR4 Expression And Function in Cutaneous T‐Cell Lymphoma Cell Lines , 2008, The Kaohsiung journal of medical sciences.
[56] Angelica Selim,et al. TNM Classification System for Primary Cutaneous Lymphomas , 2008 .
[57] A. Rook,et al. Bexarotene blunts malignant T‐cell chemotaxis in Sezary syndrome: Reduction of chemokine receptor 4‐positive lymphocytes and decreased chemotaxis to thymus and activation‐regulated chemokine , 2007, American journal of hematology.
[58] K. Rossen,et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival , 2007, Leukemia.
[59] D. Newton,et al. CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors1 , 2007, The Journal of Immunology.
[60] P. Quaglino,et al. Expression Pattern of Chemokine Receptors and Chemokine Release in Inflammatory Erythroderma and Sézary Syndrome , 2006, Dermatology.
[61] S. Whittaker,et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. , 2006, The Journal of investigative dermatology.
[62] L. Showe,et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. , 2005, The Journal of clinical investigation.
[63] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[64] L. Wilson,et al. The pathogenesis of mycosis fungoides. , 2004, The New England journal of medicine.
[65] John E. Murphy,et al. E-Selectin, Thymus- and Activation-Regulated Chemokine/CCL17, and Intercellular Adhesion Molecule-1 Are Constitutively Coexpressed in Dermal Microvessels: A Foundation for a Cutaneous Immunosurveillance System1 , 2004, The Journal of Immunology.
[66] J. Muche,et al. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. , 2003, The Journal of investigative dermatology.
[67] Koichiro Nakamura,et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. , 2003, Journal of the American Academy of Dermatology.
[68] G. Pinkus,et al. Increased CCR4 expression in cutaneous T cell lymphoma. , 2002, The Journal of investigative dermatology.
[69] W. K. Blaylock,et al. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. , 1990, Archives of dermatology.
[70] L. Laroche,et al. Decreased natural-killer-cell activity in cutaneous T-cell lymphomas. , 1983, The New England journal of medicine.
[71] Takahashi,et al. Expression of CCR 3 and CCR 4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome , 2022 .